Y Mabs Therapeutics Stock Investor Sentiment

YMAB Stock  USD 10.01  0.27  2.63%   
About 75% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Y MAbs Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at gurufocus.com         
Y-mAbs Therapeutics Inc Q1 2024 Earnings Call Transcript Highlights Navigating ...
Gurufocus Stories at Macroaxis
over six months ago at investorplace.com         
YMAB Stock Earnings Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
sbwire news
over six months ago at finance.yahoo.com         
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
Yahoo News
over six months ago at gurufocus.com         
Y-mAbs Therapeutics Reports Q1 2024 Results Aligns with EPS Projections, Misses Revenue Estimates
Gurufocus Stories at Macroaxis
over six months ago at news.google.com         
Disposition of 1682 shares by Susan Smith of Y MAbs at 16.55 subject to Rule 16b-3
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Rajah Vignesh of 35700 shares of Y MAbs subject to Rule 16b-3
Macroaxis News
over six months ago at simplywall.st         
The 7.8 percent return this week takes Y-mAbs Therapeutics shareholders one-year gains to 169
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Bailard Inc. Acquires Shares of 16900 Y-mAbs Therapeutics, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Y-mAbs Therapeutics Board Member Dr. Ber Announces Resignation - TipRanks.com - TipRanks
Google News at Macroaxis
over six months ago at globenewswire.com         
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
Macroaxis News: globenewswire.com
over six months ago at benzinga.com         
Y-mAbs to Present at 2024 ASCO Annual Meeting
benzinga news
over six months ago at news.google.com         
Y-mAbs Therapeutics Stock Price Up 7 percent - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Y-mAbs Therapeutics rises 9.6 percent this week, taking one-year gains to 161
Yahoo News
over six months ago at news.google.com         
Sapient Capital LLC Acquires New Shares in Y-mAbs Therapeutics, Inc. - Defense World
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Y MAbs that are available to investors today. That information is available publicly through YMAB media outlets and privately through word of mouth or via YMAB internal channels. However, regardless of the origin, that massive amount of YMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Y MAbs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Y MAbs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Y MAbs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Y MAbs alpha.

Y MAbs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Selling Y-mAbs Therapeutics, Inc. Insider Sells 65,000 Shares of Stock
09/18/2024
2
Disposition of 22831 shares by Thomas Gad of Y MAbs at 4.38 subject to Rule 16b-3
09/19/2024
3
Insider Trading
09/27/2024
4
Disposition of 722 shares by Ber Gerard of Y MAbs at 12.0 subject to Rule 16b-3
10/04/2024
5
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA in Japan
11/04/2024
6
What To Expect From Y-mAbs Therapeutics Inc Q3 2024 Earnings
11/07/2024
7
Paradigm Biocapital Advisors LP Bolsters Position in Y-mAbs Therapeutics Inc
11/15/2024
8
The Market Doesnt Like What It Sees From Y-mAbs Therapeutics, Inc.s Revenues Yet As Shares Tumble 26
11/19/2024
9
Y-mAbs Omburtamab Failure The Critical Turning Point And 19.65M Shareholder Settlement
11/22/2024
10
Y-mAbs to Participate at Citis 2024 Global Healthcare Conference
11/27/2024
11
Acquisition by Wg Biotech Aps of 30671 shares of Y MAbs at 5.8125 subject to Rule 16b-3
12/06/2024
12
We Think Y-mAbs Therapeutics Can Afford To Drive Business Growth
12/10/2024

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Bonds Directory
Find actively traded corporate debentures issued by US companies
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Content Syndication
Quickly integrate customizable finance content to your own investment portal
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.